Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Olema Pharmaceuticals, Inc. (OLMA : NSDQ)
 
 • Company Description   
Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.

Number of Employees: 96

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.63 Daily Weekly Monthly
20 Day Moving Average: 817,339 shares
Shares Outstanding: 68.42 (millions)
Market Capitalization: $316.79 (millions)
Beta: 1.90
52 Week High: $16.62
52 Week Low: $2.86
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 9.98% 6.68%
12 Week 9.98% -4.67%
Year To Date -20.58% -24.97%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
780 Brannan Street
-
San Francisco,CA 94103
USA
ph: 415-651-3316
fax: -
ir@olema.com http://www.olema.com
 
 • General Corporate Information   
Officers
Sean Bohen - President and Chief Executive Officer
Shane Kovacs - Chief Operating and Financial Officer
Ian Clark - Director
Cynthia Butitta - Director
Cyrus L. Harmon - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68062P106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 68.42
Most Recent Split Date: (:1)
Beta: 1.90
Market Capitalization: $316.79 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.72 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.83
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 35.71%
vs. Previous Quarter: 29.41%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -42.31
12/31/24 - -48.34
ROA
06/30/25 - -
03/31/25 - -38.32
12/31/24 - -43.18
Current Ratio
06/30/25 - -
03/31/25 - 15.22
12/31/24 - 10.50
Quick Ratio
06/30/25 - -
03/31/25 - 15.22
12/31/24 - 10.50
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 5.61
12/31/24 - 7.14
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©